Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 11/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 7/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 4/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.55 |
| ▸ | RELA | Q04206 | 4/20 | 0.55 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119200 | 1.00 | MAPT (0.61) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL30385875 | 0.85 | KDM4E (0.58) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL28914531 | 0.85 | KDM4E (0.58) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL557792 | 0.84 | PIK3CG (0.61) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL29011073 | 0.80 | MAPT (0.53) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL30387174 | 0.80 | MAPT (0.53) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL29442076 | 0.79 | NPC1 (0.61) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL12850681 | 0.79 | LMNA (0.66) | MAPTLMNACYP1A2THRBALOX15 | |
| SCHEMBL9105844 | 0.79 | NPC1 (0.61) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL903255 | 0.79 | NPC1 (0.61) | MAPTRAB9ANPC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104312-A1 | STABLE MOMETASONE FUROATE COMPOSITIONS | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2026-05-21 | — | — | WO | claimed |
| EP-2922553-B1 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | GLENMARK SPECIALTY SA (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-3806946-B1 | SYSTEMS AND METHODS FOR SINUS ACCESS | FIAGON GMBH (DE) | 2025-10-15 | — | — | EP | claimed |
| EP-3713918-B1 | SULFASALAZINE SALTS, PRODUCTION PROCESSES AND USES | MEDAC GES FUER KLINISCHE SPEZIALPRAEPARATE MBH (DE) | 2025-07-23 | — | — | EP | claimed |
| EP-3943073-B1 | BIODEGRADABLE POLYMER MICROPARTICLE CONTAINING STEROID-BASED DRUG AND PREPARATION METHOD THEREFOR | REGENBIOTECH INC (KR) | 2025-03-26 | — | — | EP | claimed |
| EP-3755375-B1 | TREATMENT OF ALLERGIC RHINITIS IN PEDIATRIC SUBJECTS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | GLENMARK SPECIALTY SA (CH) | 2025-03-05 | — | — | EP | claimed |
| EP-3791826-B1 | SELF-EXPANDING DEVICES | INTERSECT ENT INC (US) | 2025-01-29 | — | — | EP | claimed |
| EP-3866894-B1 | PHARMACEUTICAL ADMINISTRATION TO NEONATES, INFANTS AND CHILDREN | VECTURA DELIVERY DEVICES LTD (GB) | 2025-01-15 | — | — | EP | claimed |
| EP-3431096-B1 | GLUCOCORTICOID COMBINED WITH POLYETHYLENE GLYCOL-MODIFIED INTERLEUKIN-2 FOR TREATING RESPIRATORY DISEASE | XIE YANHUI (CN) | 2024-12-18 | — | — | EP | claimed |
| US-RE37781-E1 | VIRICIDES, PROTEASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2002-07-02 | — | — | US | claimed |
| US-5811422-A | USEFUL FOR TREATING VIRAL INFECTIONS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-22 | — | — | US | claimed |
| EP-0837855-A4 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | DU PONT MERCK PHARMA (US) | 1998-09-02 | — | — | EP | claimed |
| EP-0837855-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-04-29 | — | — | EP | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| US-5610294-A | VIRAL TREATMENT | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-03-11 | — | — | US | claimed |
| WO-1996040652-A1 | METHOD FOR PREPARING N-MONOSUBSTITUTED AND N,N'-DISUBSTITUTED UNSYMMETRICAL CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996029329-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| US-5532357-A | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600696-B2 | Aromatic compounds | CCR1, CCRL2, AHR | MAPT 4404/4885LMNA 832/4885CYP1A2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.